Cross Country Healthcare (CCRN)
(Delayed Data from NSDQ)
$14.81 USD
+0.44 (3.06%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $14.80 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CCRN 14.81 +0.44(3.06%)
Will CCRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CCRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCRN
Cross Country (CCRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Cross Country Healthcare (CCRN) Lags Q2 Earnings Estimates
CCRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Cross Country Healthcare (CCRN) Stock We Don't?
Compared to Estimates, Cross Country (CCRN) Q1 Earnings: A Look at Key Metrics
New Strong Sell Stocks for February 27th
Other News for CCRN
Cross Country Named Most Loved Workplace? for 2024
Cross Country Healthcare to Attend the Morgan Stanley 22nd Annual Global Healthcare Conference and the 17th Annual Barrington Research Virtual Fall Investment Conference
Buy Rating Affirmed for Cross Country Healthcare Amidst Resilient Q2 Performance and Strategic Growth Potential
Cross Country Healthcare (CCRN) Receives a Rating Update from a Top Analyst
Benchmark Co. Reaffirms Their Buy Rating on Cross Country Healthcare (CCRN)